|
|||||
|
|
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes |
|
| Authors: | Setareh Shams’ili Janet de Beukelaar Jan Willem Gratama Herbert Hooijkaas Martin van den Bent Mars van’t Veer Peter Sillevis Smitt MD PhD |
| Institution: | (1) Dept. of Neurology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands;(2) Dept. of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands;(3) Dept. of Medical Oncology, Laboratory for Clinical and Tumor Immunology, Rotterdam, The Netherlands;(4) Dept. of Immunology, Erasmus MC, Rotterdam, The Netherlands;(5) Dept. of Hematology, Erasmus MC, Rotterdam, The Netherlands |
| Abstract: | Abstract Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted. |
| Keywords: | paraneoplastic neurological syndromes anti-Hu anti-Yo rituximab |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |